Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 58Colonic Neoplasms 24Rectal Neoplasms 22Neoplasms 19Pancreatic Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 9Stomach Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Small Cell Lung Carcinoma 5Lung Neoplasms 5Glioma 5Glioblastoma 5Brain Neoplasms 5Neuroblastoma 4Gliosarcoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Renal Cell 4Melanoma 3Intestinal Neoplasms 3Gastrointestinal Neoplasms 3Breast Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Sarcoma, Ewing 2Recurrence 2Rectal Diseases 2Ovarian Neoplasms 2Oligodendroglioma 2

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × Irinotecan × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00053833 2013-11-08

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

SWOG Cancer Research Network

Phase 2 Terminated
2 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡